129 related articles for article (PubMed ID: 37585199)
21.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
22. CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross-sectional descriptive trial.
Arnaut JRMB; Guimarães IDS; Dos Santos ACE; Rodrigues EM; Machado JRDS; de Melo AC
Int J Dermatol; 2023 Aug; 62(8):1060-1066. PubMed ID: 37322831
[TBL] [Abstract][Full Text] [Related]
23. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
24. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
[TBL] [Abstract][Full Text] [Related]
25. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.
Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N;
J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
27. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1.
Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO
Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626
[TBL] [Abstract][Full Text] [Related]
28. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
29. Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.
Thomas L; Kluwe L; Chuzhanova N; Mautner V; Upadhyaya M
Neurogenetics; 2010 Oct; 11(4):391-400. PubMed ID: 20358387
[TBL] [Abstract][Full Text] [Related]
30. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
31. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
[TBL] [Abstract][Full Text] [Related]
32. Pediatric melanoma in melanoma-prone families.
Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
[TBL] [Abstract][Full Text] [Related]
33. Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome.
Solomon DA; Kim JS; Yang XR; Tucker MA; Goldstein AM; Samuels Y; Waldman T
Pigment Cell Melanoma Res; 2009 Aug; 22(4):489-91. PubMed ID: 19500277
[No Abstract] [Full Text] [Related]
34. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center.
Kim DH; Murovic JA; Tiel RL; Moes G; Kline DG
J Neurosurg; 2005 Feb; 102(2):246-55. PubMed ID: 15739552
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
36. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
[TBL] [Abstract][Full Text] [Related]
37. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
[TBL] [Abstract][Full Text] [Related]
38. 9p21.3 Microdeletion involving
Jensen MR; Stoltze U; Hansen TVO; Bak M; Sehested A; Rechnitzer C; Mathiasen R; Scheie D; Larsen KB; Olsen TE; Muhic A; Skjøth-Rasmussen J; Rossing M; Schmiegelow K; Wadt K
Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35422439
[TBL] [Abstract][Full Text] [Related]
39. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
[TBL] [Abstract][Full Text] [Related]
40. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
